Viromed Medical AG, a medical technology company specializing in cold plasma applications, has completed the conversion of its share capital from bearer shares to registered shares following a resolution approved at its Annual General Meeting on July 29, 2025. The change, which became effective upon entry into the commercial register on August 8, 2025, represents a strategic shift in how the company manages its shareholder base and communicates with investors.
The technical conversion process will occur on the evening of January 16, 2026, when all 21,250,000 bearer shares currently held under ISIN DE000A3MQR65 will be deregistered by custodian banks and Clearstream Banking AG in Frankfurt. Shareholders will receive one new registered share for each previous bearer share, with each share representing €1.00 of share capital under the new ISIN DE000A40VZN7. The company has excluded the right to individual certification, instead maintaining the share capital in a global certificate deposited with Clearstream Banking AG.
Trading of the existing bearer shares concluded on January 14, 2026, with the new registered shares commencing stock exchange trading under the new ISIN on January 15, 2026. Importantly, the conversion does not alter shareholders' proportional ownership or associated rights, nor does it restrict their ability to sell shares, as registered share transfers do not require company approval.
This transition from bearer to registered shares enables Viromed to establish direct communication channels with its shareholders, a capability not possible with anonymous bearer shares. For business and technology leaders monitoring the medical technology sector, this move signals Viromed's maturation as a publicly traded company and its commitment to enhanced corporate governance. The ability to identify and communicate directly with shareholders provides management with valuable insights into investor composition and enables more targeted engagement on strategic initiatives.
Viromed, which has been listed since October 2022, operates through its wholly owned subsidiary Viromed Medical GmbH, focusing on distributing innovative cold plasma technology for medical applications. The company has established a broad customer base in the DACH region and beyond, with ambitions to advance cold plasma technology in medicine and realize corresponding growth potential in coming years. Additional information about the company is available at https://www.viromed-medical-ag.de.
The conversion to registered shares represents more than an administrative change; it reflects Viromed's positioning for future growth in the competitive medical technology landscape. As companies in the healthcare technology sector increasingly prioritize investor relations and transparency, Viromed's move aligns with broader industry trends toward enhanced shareholder engagement. For investors, this transition offers greater visibility into ownership structures while maintaining the liquidity advantages of publicly traded securities, potentially making the company more attractive to institutional investors who value direct corporate communication.
